CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01339039
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:45.261628+00:00
- Published At
- 2017-11-17T00:00:00+00:00
- Record Updated At
- 2017-11-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["High Grade Glioma: Glioblastoma (GBM)", "High Grade Glioma: Gliosarcoma", "Anaplastic Astrocytoma (AA)", "Anaplastic Oligodendroglioma (AO)", "Mixed Anaplastic Oligoastrocytoma (AOA)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-11-17"- protocolSection.identificationModule.nctId
"NCT01339039"- protocolSection.identificationModule.officialTitle
"Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.